AbGenomics International

AltruBio, formerly known as AbGenomics International, is a clinical-stage biopharmaceutical company specializing in the development of novel antibody-based therapies for immune-mediated diseases and cancer. The company's lead program, neihulizumab, is a first-in-class monoclonal antibody targeting the PSGL-1/CD162 pathway to induce the selective depletion of activated T cells. This approach aims to treat T-cell driven inflammatory conditions such as graft-versus-host disease and psoriatic arthritis without causing broad immunosuppression. Additionally, the company leverages a proprietary antibody-drug conjugate platform to develop targeted treatments for solid tumors including gastric and pancreatic cancers. AltruBio is headquartered in San Jose, California, and continues to advance its pipeline through clinical trials in both immunology and oncology.